OnKure Therapeutics, Inc. 8-K

What Happened On May 5, 2026, OnKure Therapeutics, Inc. (OKUR) filed a Form 8-K (Item 2.02) to disclose that it issued a press release reporting its financial results for the quarter ended March 31, 2026. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference into the 8-K.

Key Details

• Filing date: May 5, 2026; quarter covered: Q1 ended March 31, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition).
• Exhibit: Press release attached as Exhibit 99.1 (incorporated by reference).
• Legal note (Item 9.01): the furnished information and exhibit are not deemed “filed” under Section 18 of the Exchange Act and are not incorporated by reference into other filings unless expressly stated.

Why It Matters This 8-K notifies investors that OnKure has released its latest quarterly earnings information and provides the press release for review. Investors should read Exhibit 99.1 for the full financial details (earnings, revenue, guidance, or other metrics) because the 8-K itself does not include numeric results beyond noting the press release. The Item 9.01 disclosure clarifies the limited legal status of the furnished materials.